Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Freeman

Showing results (11-20 of 143) with videos related to

Pageof 15
Sort By:
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Preclinical Advances in Combined-Modality Cancer Immunotherapy With Radiation TherapyClayton A Smith, Michael L Freeman
Toxicology and Applied Pharmacology|January 19, 2010
Nrf2 in toxicology and pharmacology: the good, the bad and the ugly?Jingbo Pi, Michael L Freeman, Masayuki Yamamoto
Pathogens & Immunity|October 22, 2020
Novel Strategies to Combat CMV-Related Cardiovascular DiseaseElena Vasilieva, Sara Gianella, Michael L Freeman
Current HIV/AIDS Reports|January 27, 2016
Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV InfectionMichael L Freeman, Michael M Lederman, Sara Gianella
Chemical Research in Toxicology|December 20, 2005
Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphaneFei Hong, Michael L Freeman, Daniel C Liebler
NPJ Cardiovascular Health|June 2, 2025
Mechanisms and implications of vascular-homing CD8 T cells in atherosclerosisXi Su, Katelyn A O'Hare, Michael L Freeman
Toxicology and Applied Pharmacology|June 30, 2009
Cysteine-based regulation of the CUL3 adaptor protein Keap1Konjeti R Sekhar, Girish Rachakonda, Michael L Freeman
Pathogens & Immunity|December 5, 2024
Inflammation and Microbial Translocation Correlate with Reduced MAIT Cells in People with HIVAngela Ryu, Brian M Clagett, Michael L Freeman
Oncogene|October 3, 2002
Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2Konjet R Sekhar, Xue Xian Yan, Michael L Freeman
Pathogens & Immunity|July 10, 2023
Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and PreventionDavid R Sweet, Michael L Freeman, David A Zidar
Pageof 15

Showing results (11-20 of 143) with videos related to

Sort By:
Pageof 15
International Journal of Radiation Oncology, Biology, Physics|December 25, 2015
Preclinical Advances in Combined-Modality Cancer Immunotherapy With Radiation TherapyClayton A Smith, Michael L Freeman
Toxicology and Applied Pharmacology|January 19, 2010
Nrf2 in toxicology and pharmacology: the good, the bad and the ugly?Jingbo Pi, Michael L Freeman, Masayuki Yamamoto
Pathogens & Immunity|October 22, 2020
Novel Strategies to Combat CMV-Related Cardiovascular DiseaseElena Vasilieva, Sara Gianella, Michael L Freeman
Current HIV/AIDS Reports|January 27, 2016
Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV InfectionMichael L Freeman, Michael M Lederman, Sara Gianella
Chemical Research in Toxicology|December 20, 2005
Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphaneFei Hong, Michael L Freeman, Daniel C Liebler
NPJ Cardiovascular Health|June 2, 2025
Mechanisms and implications of vascular-homing CD8 T cells in atherosclerosisXi Su, Katelyn A O'Hare, Michael L Freeman
Toxicology and Applied Pharmacology|June 30, 2009
Cysteine-based regulation of the CUL3 adaptor protein Keap1Konjeti R Sekhar, Girish Rachakonda, Michael L Freeman
Pathogens & Immunity|December 5, 2024
Inflammation and Microbial Translocation Correlate with Reduced MAIT Cells in People with HIVAngela Ryu, Brian M Clagett, Michael L Freeman
Oncogene|October 3, 2002
Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2Konjet R Sekhar, Xue Xian Yan, Michael L Freeman
Pathogens & Immunity|July 10, 2023
Immunohematologic Biomarkers in COVID-19: Insights into Pathogenesis, Prognosis, and PreventionDavid R Sweet, Michael L Freeman, David A Zidar
Pageof 15